Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
Signe Sparre Beck-Nielsen,
Henrik Hasle,
Akmal Safwat,
Kestutis Valancius,
Bente Langdahl,
Ebbe Stender Hansen
Affiliations
Signe Sparre Beck-Nielsen
Centre for Rare Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulvard 82, DK-8200 Aarhus N, Denmark; Corresponding author at: Centre for Rare Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark.
Henrik Hasle
Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulvard 82, DK-8200 Aarhus N, Denmark; Paediatrics and Adolescent Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark
Akmal Safwat
Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark
Kestutis Valancius
Spine Surgery Unit, Department of Orthopedic Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark
Bente Langdahl
Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulvard 82, DK-8200 Aarhus N, Denmark; Department of Endocrinology, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark
Ebbe Stender Hansen
Spine Surgery Unit, Department of Orthopedic Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulvard 99, DK-8200 Aarhus N, Denmark
A giant cell tumour of bone presented in the os sacrum of a prepubertal girl. Surgery with reconstruction was performed, but total resection was impossible. Zoledronate failed to avoid tumour regrowth, and treatment was changed to denosumab, despite not being recommended for use in growing children. Denosumab treatment for 21 months reduced and stabilized tumour size, the girl became pain free with asymptomatic side effects as mild hypocalcemia, hypophosphatemia and sclerosis of newly formed bone.
